Pharmaceutical outcomes

In a tiny fraction of cases, a quick formula can be used. For most cases, the analysis uses an options tree, with one leaf per possible outcome. However, this falls prey to the curse of dimensionality —the number of leaves on the tree grows exponentially in the number of risk and decision dimensions considered. Thus only a limited, simple set of situations can be optimized in this way because one has to severely limit the decisions and risks that are considered. Tools available to help automate and simplify options analysis, widely used in pharmaceutical project evaluation, include Excel addons such as R1SK [11] and more graphically based solutions such as DPL [12]. Both of these support the creation and evaluation of decision trees and of influence diagrams Figure 11.2 shows a simple example of each of these. A primer in applied decision theory is Clemen s book Making Hard Decisions, other sources may be found in the website of James Vornov, Director of Clinical Research at Guildford Pharmaceuticals, a recent convert to decision theory for options analysis [13]. 

Examining the inspectors workloads will also help to establish reasons for the success or failure of the inspection process. EHiring their inspection of pharmaceutical establishments, inspectors may learn of the presence of unregistered products, counterfeit products, etc. Quantitative information on these and other issues is valuable as an outcome measure. 

Cancer treatments have exploded technologically in the last couple of decades. The fields of radiation therapy, surgery, and pharmaceuticals have had numerous developments, so patients are receiving not only less toxic treatments but also treatments that have improved outcomes over those of 15 years ago. Supportive-care therapies have improved, so patients may be at... 

Medication Outcomes Coordinator Pharmaceutical Department St. Jude Children s Research Hospital Memphis, Tennessee Chapter 63 Anemias... 

Packaging that is developed according to patient education principals can serve as a strong reminder or motivational aid to the patient. The complete package, a new concept recently proposed, is the most advanced type of compliance packaging. The proponents of this concept recommend that pharmaceutical companies expand their definition of a product beyond that of the medication. The complete package consists of the medication plus the complete set of compliance packaging and the educational materials necessary to help the patient obtain the desired therapeutic outcome. 

Biopharmaceutical issues to be addressed will include a discussion of the pharmaceutical development process as it relates to in vivo and in vitro performance and the general approach taken concerning bioavailability, bioequivalence, and in vitro dissolution profiles. There should be a comparative analysis of relevant studies—objectives, study design, conduct, outcome, and data analyses. The effects of formulation changes (including different strengths of product and... 

The sterilization processes described in the Ph Eur are preferred, especially terminal sterilization in the final container alternative processes have to be justified. All sterilization processes will need to be described and appropriate in-process controls and limits included. Where Ph Eur prescriptions are followed, there should be a statement to this effect in the application. Most of this information should be discussed in the development pharmaceutics section. Reference is made to the specific guidelines on ethylene oxide sterilization and irradiation sterilization, which are discussed further below. The possibility of parametric release for terminal processes such as saturated steam and irradiation is mentioned (see below). For all sterile products there should be a sterility requirement included in the finished product specification regardless of the outcome of validation studies. 

In Chapter 8, professor J.L. Pinto Prades of Pompeu Fabra University and X. Badla Llach of the Health Outcomes Research Unit at Santa Creu i Sant Pau Hospital take a look at the potential contribution of economic evaluation to the regulation and control of public spending on pharmaceuticals. The authors focus on observing how economic evaluation can be used in pharmaceutical policy. To this end, they distinguish and analyse the potential this instrument has in six distinct areas the approval of pharmaceuticals by health... 

In general, however, this initial analysis is open to doubt, in view of the high degree of intervention in Spanish drug prices and the fact that authorized prices are regarded as maximum prices, although this is not always sufficiently stressed. These two factors complicate any forecast of the possible outcome of the competition induced by RP in the Spanish pharmaceutical market. 

---